Hematology

The median charge of treatment for a 6-day hospital stay totals $37,000 in young cancer patients in need of stem cell transplants.

The FDA has expanded the use of Amgen's blinatumomab (Blincyto) to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients.

New treatment for mast cell leukemia could improve quality-of-life and overall survival.

Novel drug is a bispecific T cell engager (BiTE) that targets the B-cell maturation antigen in multiple myeloma.

Factors other than race or ethnicity influence outcomes in multiple myeloma.

The Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow, will allow pharmacists to obtain continuing education credits while staying on top of the latest oncology advances.

Self-reported psychological well-being superior in patients with leukemia after a bone marrow transplant compared with peripheral blood transplants.

The drug received breakthrough therapy designation for this pending indication in July 2016.

Top news of the week in oncology, and cancer drug development.

Genetics influence survival in patients with leukemia.

MCL-1 inhibitor drug class could potentially cure the bone marrow cancer.

Top news of the day from across the health care landscape.

Monoclonal antibody combination could offer less toxic acute lymphoblastic leukemia treatment.

Damage associated with leukemia occurs in regions where DNA is transcribed actively.

Patients who relapse following a stem cell transplant for leukemia, lymphoma, or multiple myeloma may benefit from ipilimumab.

Chimeric antigen receptor T cell therapy targets advanced forms of leukemia and lymphoma.

Multiple myeloma cells show greater ability to spread in obese and morbidly obese patients.

Next-generation sequencing technology sheds new light on childhood leukemia.

Uncialamycin may effectively treat various cancer types, including gastric, lung, and ovarian cancers.

Rapalink able to inhibit growth in drug-resistant tumors across different cancer types.

New drug class offers hope for lymphomas and leukemia.

Study suggests an approximately 2.5-year survival increase compared with placebo or no maintenance in patients with multiple myeloma.

Salicylic acid was able to suppress the p300 protein and stop leukemia progression.

Recent advances and updates in oncology and cancer drug development.

Older African American multiple myeloma patients have lower rates of access to autologous stem cell transplants and and novel combination therapies.